Display options
Cite
Dobrovinskaya O, Valencia-Cruz G, Castro-Sánchez L, et al. Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia. Front Pharmacol. 2016;7:290doi: 10.3389/fphar.2016.00290.
Dobrovinskaya, O., Valencia-Cruz, G., Castro-Sánchez, L., Bonales-Alatorre, E. O., Liñan-Rico, L., & Pottosin, I. (2016). Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia. Frontiers in pharmacology, 7290. https://doi.org/10.3389/fphar.2016.00290
Dobrovinskaya, Oxana, et al. "Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia." Frontiers in pharmacology vol. 7 (2016): 290. doi: https://doi.org/10.3389/fphar.2016.00290
Dobrovinskaya O, Valencia-Cruz G, Castro-Sánchez L, Bonales-Alatorre EO, Liñan-Rico L, Pottosin I. Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia. Front Pharmacol. 2016 Aug 31;7:290. doi: 10.3389/fphar.2016.00290. eCollection 2016. PMID: 27630569; PMCID: PMC5005329.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Aug 31;7:290. doi: 10.3389/fphar.2016.00290. eCollection 2016.

Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Frontiers in pharmacology

Oxana Dobrovinskaya, Georgina Valencia-Cruz, Luis Castro-Sánchez, Edgar O Bonales-Alatorre, Liliana Liñan-Rico, Igor Pottosin

Affiliations

  1. Centro Universitario de Investigaciones Biomédicas, Universidad de Colima Colima, México.
  2. Centro Universitario de Investigaciones Biomédicas, Universidad de ColimaColima, México; Consejo Nacional de Ciencia y TecnologíaMéxico City, México.

PMID: 27630569 PMCID: PMC5005329 DOI: 10.3389/fphar.2016.00290

Abstract

Various types of non-neuronal cells, including tumors, are able to produce acetylcholine (ACh), which acts as an autocrine/paracrine growth factor. T lymphocytes represent a key component of the non-neuronal cholinergic system. T cells-derived ACh is involved in a stimulation of their activation and proliferation, and acts as a regulator of immune response. The aim of the present work was to summarize the data about components of cholinergic machinery in T lymphocytes, with an emphasis on the comparison of healthy and leukemic T cells. Cell lines derived from acute lymphoblastic leukemias of T lineage (T-ALL) were found to produce a considerably higher amount of ACh than healthy T lymphocytes. Additionally, ACh produced by T-ALL is not efficiently hydrolyzed, because acetylcholinesterase (AChE) activity is drastically decreased in these cells. Up-regulation of muscarinic ACh receptors was also demonstrated at expression and functional level, whereas nicotinic ACh receptors seem to play a less important role and not form functional channels in cells derived from T-ALL. We hypothesized that ACh over-produced in T-ALL may act as an autocrine growth factor and play an important role in leukemic clonal expansion through shaping of intracellular Ca(2+) signals. We suggest that cholinergic machinery may be attractive targets for new drugs against T-ALL. Specifically, testing of high affinity antagonists of muscarinic ACh receptors as well as antagomiRs, which interfere with miRNAs involved in the suppression of AChE expression, may be the first choice options.

Keywords: T leukemia; T lymphocyte; acetylcholine; acetylcholinesterase; calcium signaling; choline acetyltransferase; muscarinic receptor non-neuronal cholinergic system

References

  1. Biochem Biophys Res Commun. 2009 Dec 25;390(4):1102-5 - PubMed
  2. J Neuroimmunol. 2002 May;126(1-2):86-98 - PubMed
  3. Life Sci. 2004 Dec 3;76(3):263-80 - PubMed
  4. Mol Cell Biol. 1997 Mar;17(3):1201-11 - PubMed
  5. Chem Biol Interact. 2016 Nov 25;259(Pt B):257-265 - PubMed
  6. Biopharm Drug Dispos. 2014 Nov;35(8):431-49 - PubMed
  7. J Neuroimmunol. 2007 Sep;189(1-2):69-74 - PubMed
  8. EMBO J. 1991 Jul;10(7):1671-5 - PubMed
  9. Life Sci. 1997;60(13-14):1093-100 - PubMed
  10. J Neurosci. 1998 Jul 1;18(13):4946-52 - PubMed
  11. Annu Rev Immunol. 2015;33:291-353 - PubMed
  12. J Neurosci. 2013 Jun 26;33(26):10667-75 - PubMed
  13. Clin Exp Dermatol. 2005 Sep;30(5):557-64 - PubMed
  14. Inflamm Res. 2009 Jan;58(1):38-44 - PubMed
  15. Br J Haematol. 1982 Feb;50(2):241-5 - PubMed
  16. Mol Pharmacol. 1993 Mar;43(3):356-64 - PubMed
  17. Exp Biol Med (Maywood). 2006 May;231(5):490-504 - PubMed
  18. Pharmacol Rev. 1998 Jun;50(2):279-90 - PubMed
  19. Biochim Biophys Acta. 2016 Mar;1863(3):449-63 - PubMed
  20. Diagn Interv Radiol. 2016 Jan-Feb;22(1):75-89 - PubMed
  21. Neuroimmunomodulation. 1999 Jan-Apr;6(1-2):51-5 - PubMed
  22. J Biol Chem. 2008 May 23;283(21):14559-70 - PubMed
  23. J Neurochem. 1998 Aug;71(2):630-5 - PubMed
  24. Nat Rev Immunol. 2009 Jun;9(6):418-28 - PubMed
  25. Nat Rev Cancer. 2011 Nov 17;11(12):835-48 - PubMed
  26. Naunyn Schmiedebergs Arch Pharmacol. 2000 Jul;362(1):14-21 - PubMed
  27. J Leukoc Biol. 2015 Feb;97(2):247-57 - PubMed
  28. Chem Biol Interact. 2013 Mar 25;203(1):113-9 - PubMed
  29. Biochem Biophys Res Commun. 2013 May 3;434(2):273-9 - PubMed
  30. J Neuroimmunol. 2012 Mar;244(1-2):16-22 - PubMed
  31. Pflugers Arch. 2008 Sep;456(6):1037-48 - PubMed
  32. Inflamm Bowel Dis. 2013 Jun;19(7):1346-53 - PubMed
  33. Exp Hematol. 2015 Aug;43(8):625-39 - PubMed
  34. Science. 2004 Oct 8;306(5694):269-71 - PubMed
  35. Carcinogenesis. 2000 Oct;21(10):1789-93 - PubMed
  36. J Immunol. 2007 Sep 1;179(5):2889-98 - PubMed
  37. PLoS One. 2012;7(12 ):e53170 - PubMed
  38. Biochim Biophys Acta. 2013 Feb;1828(2):699-707 - PubMed
  39. Cancer Cell. 2015 Jun 8;27(6):755-68 - PubMed
  40. J Neuroimmunol. 2002 Nov;132(1-2):147-55 - PubMed
  41. Mol Med. 2015 Apr 03;21:323-36 - PubMed
  42. J Neuroimmunol. 1998 Jan;81(1-2):31-7 - PubMed
  43. J Neurochem. 2007 Jul;102(2):479-92 - PubMed
  44. Immunology. 1997 Oct;92(2):201-5 - PubMed
  45. Front Mol Neurosci. 2014 Feb 10;7:9 - PubMed
  46. J Neurosci. 2006 Sep 27;26(39):9851-9 - PubMed
  47. Pflugers Arch. 2015 May;467(5):945-58 - PubMed
  48. J Cell Biol. 1993 May;121(3):643-54 - PubMed
  49. Life Sci. 2009 Sep 9;85(11-12):444-9 - PubMed
  50. Trends Neurosci. 2005 Jul;28(7):343-5 - PubMed
  51. Pharmacol Ther. 2000 Apr;86(1):29-48 - PubMed
  52. Handb Exp Pharmacol. 2012;(208):451-68 - PubMed
  53. Mol Cell Biochem. 2001 Dec;228(1-2):57-72 - PubMed
  54. J Neuroimmunol. 2011 Aug 15;237(1-2):13-22 - PubMed
  55. Am J Physiol. 1996 May;270(5 Pt 1):L722-8 - PubMed
  56. Clin Cancer Res. 1999 Sep;5(9):2532-9 - PubMed
  57. J Neurochem. 1978 Jan;30(1):15-21 - PubMed
  58. FEBS Lett. 2010 Feb 19;584(4):817-24 - PubMed
  59. Leukemia. 2008 Dec;22(12):2142-50 - PubMed
  60. Nature. 2002 Dec 19-26;420(6917):853-9 - PubMed
  61. Cancer Res. 2003 Jan 1;63(1):214-21 - PubMed
  62. Immunol Rev. 2009 Sep;231(1):59-87 - PubMed
  63. Pediatr Clin North Am. 2015 Feb;62(1):47-60 - PubMed
  64. J Nucl Med. 1997 Jun;38(6):842-7 - PubMed
  65. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):345-62 - PubMed
  66. Neuropharmacology. 2001 Mar;40(3):358-65 - PubMed
  67. Science. 2011 Oct 7;334(6052):98-101 - PubMed
  68. J Cutan Pathol. 1997 Mar;24(3):137-44 - PubMed
  69. Clin Chim Acta. 2009 Apr;402(1-2):114-8 - PubMed
  70. J Cancer Res Clin Oncol. 2003 May;129(5):272-8 - PubMed
  71. Antiinflamm Antiallergy Agents Med Chem. 2013;12(2):136-40 - PubMed
  72. Neurochem Int. 1994 Aug;25(2):103-9 - PubMed
  73. Front Biosci (Elite Ed). 2010 Jun 01;2:928-39 - PubMed
  74. Leukemia. 2006 Sep;20(9):1496-510 - PubMed
  75. CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103 - PubMed
  76. Life Sci. 2012 Nov 27;91(21-22):981-5 - PubMed
  77. Recent Pat CNS Drug Discov. 2014;9(2):85-100 - PubMed
  78. J Cutan Pathol. 2008 Sep;35(9):809-15 - PubMed
  79. Life Sci. 2007 May 30;80(24-25):2314-9 - PubMed
  80. Biomed Rep. 2016 May;4(5):515-518 - PubMed
  81. Cell Signal. 2014 Jan;26(1):149-61 - PubMed
  82. Nat Med. 2007 Jun;13(6):736-41 - PubMed
  83. Expert Rev Mol Diagn. 2006 Nov;6(6):821-9 - PubMed
  84. J Biol Chem. 1996 Nov 1;271(44):27229-32 - PubMed
  85. J Thorac Oncol. 2014 Feb;9(2):170-8 - PubMed
  86. Prog Brain Res. 2004;145:59-66 - PubMed
  87. Life Sci. 2003 Dec 26;74(6):675-96 - PubMed
  88. Neurosci Lett. 1999 Jan 8;259(2):71-4 - PubMed
  89. J Pharmacol Sci. 2008 Feb;106(2):186-92 - PubMed
  90. Genes Immun. 2011 Apr;12(3):222-30 - PubMed
  91. Am J Physiol Cell Physiol. 2009 Feb;296(2):C221-32 - PubMed
  92. Ann N Y Acad Sci. 2009 Jan;1152:100-12 - PubMed
  93. Biochem Soc Trans. 2003 Dec;31(Pt 6):1182-5 - PubMed
  94. Immunol Lett. 1995 Jan;44(2-3):217-20 - PubMed
  95. Cell Res. 2013 Nov;23 (11):1270-83 - PubMed
  96. Life Sci. 1997;60(13-14):1039-45 - PubMed
  97. Life Sci. 2012 Nov 27;91(21-22):1027-32 - PubMed
  98. Immune Netw. 2011 Jun;11(3):135-54 - PubMed
  99. Nat Rev Cancer. 2009 Mar;9(3):195-205 - PubMed
  100. Life Sci. 2003 Mar 28;72 (18-19):2155-8 - PubMed
  101. Immunol Invest. 2014;43(7):667-74 - PubMed
  102. J Comp Neurol. 2013 Nov;521(16):3741-67 - PubMed
  103. J Physiol. 2015 Oct 15;593(20):4531-48 - PubMed
  104. Gen Pharmacol. 2000 Aug;35(2):71-5 - PubMed
  105. J Biol Chem. 2001 Feb 23;276(8):5622-8 - PubMed
  106. Cell. 1994 Jan 28;76(2):263-74 - PubMed
  107. J Neuroimmune Pharmacol. 2010 Dec;5(4):479-88 - PubMed
  108. J Nucl Med. 1998 Jun;39(6):990-5 - PubMed
  109. J Oncol. 2016;2016:9650481 - PubMed
  110. Biochem Pharmacol. 2011 Oct 15;82(8):904-14 - PubMed
  111. Immunity. 2009 Dec 18;31(6):965-73 - PubMed
  112. Life Sci. 2003 Mar 28;72(18-19):2029-38 - PubMed
  113. EMBO J. 2013 May 29;32(11):1613-25 - PubMed
  114. Biomed Res Int. 2015;2015:750203 - PubMed
  115. J Biol Chem. 2004 Apr 30;279(18):18550-8 - PubMed
  116. Leuk Res. 1984;8(4):741-4 - PubMed
  117. Life Sci. 1987 Oct 12;41(15):1853-60 - PubMed
  118. Curr Pharm Des. 2006;12(28):3573-81 - PubMed
  119. Respir Res. 2006 Apr 12;7:65 - PubMed
  120. J Biomed Sci. 2012 Oct 17;19:90 - PubMed
  121. Nucleic Acids Res. 2014 Dec 16;42(22):13500-12 - PubMed
  122. Br J Pharmacol. 2001 Nov;134(5):951-6 - PubMed
  123. Leukemia. 2013 Dec;27(12):2289-300 - PubMed
  124. Curr Mol Med. 2014;14(9):1126-38 - PubMed
  125. Neurosci Lett. 1999 Apr 30;266(1):17-20 - PubMed
  126. Cancer Res. 2007 Apr 15;67(8):3936-44 - PubMed
  127. J Biol Chem. 2003 May 23;278(21):19565-73 - PubMed
  128. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9226-30 - PubMed
  129. Cancer Res. 2008 May 15;68(10):3573-8 - PubMed
  130. J Nucl Med. 2000 Sep;41(9):1507-13 - PubMed
  131. Leukemia. 2012 Jan;26(1):1-12 - PubMed
  132. Pharmacology. 2013;92(5-6):286-302 - PubMed
  133. J Biol Chem. 2011 Jan 7;286(1):594-606 - PubMed
  134. J Biol Chem. 1998 Jan 23;273(4):1839-42 - PubMed
  135. J Neuroimmunol. 2005 Jul;164(1-2):66-75 - PubMed
  136. J Neuroimmunol. 2005 Mar;160(1-2):154-61 - PubMed
  137. Immunol Rev. 2016 May;271(1):156-72 - PubMed
  138. Neurochem Res. 2003 Apr;28(3-4):423-9 - PubMed
  139. Clin Biochem. 2014 Jan;47(1-2):63-6 - PubMed
  140. Folia Neuropathol. 2013;51(1):65-75 - PubMed
  141. Dig Dis Sci. 2003 Aug;48(8):1431-44 - PubMed
  142. Genomics. 2001 May 1;73(3):272-83 - PubMed
  143. Jpn J Pharmacol. 2000 Oct;84(2):124-32 - PubMed
  144. Front Mol Neurosci. 2011 Oct 05;4:28 - PubMed
  145. Cancer Res. 2008 Jun 15;68(12):4693-700 - PubMed
  146. Neurosci Lett. 1996 Aug 23;214(2-3):171-4 - PubMed
  147. Microrna. 2014;2(3):158-64 - PubMed
  148. Int Immunopharmacol. 2015 Nov;29(1):127-34 - PubMed
  149. J Clin Invest. 2012 Oct;122(10):3398-406 - PubMed
  150. Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):170-7 - PubMed
  151. Blood. 1983 Mar;61(3):413-22 - PubMed
  152. Genes Chromosomes Cancer. 2015 Apr;54(4):222-34 - PubMed
  153. Auton Neurosci. 2014 May;182:65-9 - PubMed
  154. J Neuroimmunol. 1998 Feb;82(1):101-7 - PubMed
  155. J Neurosci Res. 1996 Apr 1;44(1):66-72 - PubMed
  156. Front Biosci. 2004 Sep 01;9:2063-85 - PubMed
  157. Life Sci. 2003 Mar 28;72 (18-19):2121-6 - PubMed

Publication Types